Moringa oleifera (MO) is a multipurpose plant with a high polyphenol content, which is being increasingly consumed to lessen the risk of chronic metabolic diseases such as Type 2 diabetes; however, scientific evidence from clinical trials is scarce. A double-blind, randomized, placebo-controlled, parallel group intervention study with MO leaves as a food supplement was conducted in subjects with prediabetes. They consumed six daily capsules of MO dry leaf powder (2400 mg/day) (MO, n = 31) or placebo (PLC, n = 34) over 12 weeks. Glycemia, appetite-controlling hormones and gut microbiota composition were studied. ANCOVA with the fixed factor “treatment” and the basal value as covariate was used to compare the change score between the groups. The results showed significant differences between groups in the rate of change of fasting blood glucose (FBG) and glycated hemoglobin (HbA1c), which showed opposite directions during the intervention, decreasing in MO and increasing in PLC. No different change scores were found between the groups in microbiota, hepatic and renal function markers or the appetite-controlling hormones measured. In conclusion, MO supplementation resulted in favorable changes in glycaemia markers compared to placebo in the subjects with prediabetes studied, suggesting that MO might act as a natural antihyperglycemic agent.

Different parts of the Moringa oleifera Lam. (MO) tree are consumed as food or food supplements for their nutritional and medicinal value; however, very few human studies have been published on the topic. The current work was aimed to provide ancillary analysis to the antidiabetic effects previously reported in a double-blind, randomized, placebo-controlled, parallel group intervention conducted in patients with prediabetes. Thus, the effect of MO leaves on blood and fecal inflammatory markers, serum lipid profile, plasma antioxidant capacity and blood pressure was studied in participants who consumed 6 × 400 mg capsule/day of MO dry leaf powder (MO, n = 31) or placebo (PLC, n = 34) over 12 weeks. Differences between groups were assessed using each biomarker’s change score with, adjustment for fat status and the baseline value. In addition, a decision tree analysis was performed to find individual characteristics influencing the glycemic response to MO supplementation. No differences in the biomarker’s change scores were found between the groups; however, the decision tree analysis revealed that plasma TNF-α was a significant predictor of the subject’s HbA1c response (improvement YES/NO; 77% correct classification) in the MO group. In conclusion, TNF-α seems to be a key factor to identify potential respondents to MO leaf powder.

The general lockdown decreed in Spain due to the COVID-19 pandemic interrupted the ALAS health promotion intervention aimed at the population at high risk of suffering from type 2 diabetes. We conducted a descriptive study in 2020 through a telephone survey and a comparison with baseline data to determine the impact of confinement on the lifestyles of the participants. We collected sociodemographic variables and conducted assessments before/after confinement on general health status and lifestyle (sleep, physical activity and diet). Additionally, weight, BMI and adherence to a Mediterranean diet were assessed. Descriptive statistical analyses, comparisons of pre–post confinement data and logistic regression were carried out. A total of 387 individuals responded. Among them, 31.8% reported a worse perception of health after confinement, and 63,1% reported no change. Regarding exercise, 61.1% reduced their weekly physical activity time. Regarding diet, 34,4% perceived worse quality, and 53.4% reported no change, despite the fact that 89.4% declared changes in their eating practices. Weight and BMI decreased by 3,1%, and adherence to the Mediterranean diet improved from baseline. Confinement had a negative impact on the general health, diet, sleep and physical activity of this population (at risk of diabetes); however, weight and BMI decreased, and adherence to a Mediterranean diet improved.

Background and objectives: The gut microbiota performs many functions in the host organism, and metabolites derived from its activity, such as short-chain fatty acids (SCFA), are involved in immunometabolism. Alterations in gut microbial composition play an essential role in diseases such as heart failure, kidney disease, obesity, and diabetes mellitus. The current work aimed to analyze the associations of serum and fecal inflammatory biomarkers with the microbiota and SCFA in prediabetic subjects. Methods: 65 prediabetic patients, diagnosed according to the American Diabetes Association criteria, who participated in a randomized controlled intervention study with Moringa oleifera Lam. (2.4 g/day), were included. Inflammatory markers (Serum C reactive protein [CRP] and fecal calprotectin and sIgA), gut microbiota (qPCR), and short-chain fatty acids (SCFA; GC-FID) were studied before (V0) and after a 12-week intervention (V12). Relationships were explored using principal component analysis (PCA). Lineal regression models were performed to determine the predictive variables of inflammatory markers by including SCFA and gut microbiota groups as one block of independent variables. Fat mass percentage (BIA) and treatment group were used to adjust the models. Analyses were performed for V0 and V12 separately. Results: Only for calprotectin were significant models found at V0 (p = 0.044) and V12 (p = 0.010). Lactobacillus (standardized beta, β= 0.292; p = 0.047) and Bacteroides (β = 0.430; p = 0.009) groups were significant predictors at V0 and Lactobacillus (β = 0.339; p = 0.015) and the SCFA valeric acid (β = −0.533; p = 0.014) were predictors of calprotectin in V12. For CRP, a trend was found at V12 regression (p = 0.079), with significant contributions for the Blautia coccoides–Eubacterium rectale group (β = 0.585; p = 0.016) and the categorical binomial variable “Above normal fat mass percentage” (“yes”, “no”) (β = 0.478; p < 0.001). No significant influence of the treatment group was observed. Discussion: Calprotectin levels seem to be dependent on microbiota and SCFA levels. Calprotectin showed a positive and consistent relationship with Lactobacillus spp.; however, its relationships with the Bacteroides group and valeric acid were not consistent and deserve further exploration. CRP and sIgA do not seem to be explained to a significant level by the microbiota and SCFA concentrations in this prediabetic population.